Status Epilepticus: Correcting a Benzodiazepine Dose That Was Already Too Low
A single patient, still seizing in the emergency department after an initial benzodiazepine dose that was never actually enough. The guideline dose is not in dispute — what to do about the gap already created is.
A.G., a 58-year-old woman with no prior seizure history, retired two years ago from three decades as a hospital pharmacy technician, and was found seizing on her kitchen floor by a neighbor who had stopped by to return a casserole dish. EMS gave 2mg IV lorazepam en route — a real dose, but half of what the guideline actually calls for. The American Epilepsy Society's status epilepticus guideline (Glauser et al., 2016) specifies lorazepam 0.1mg/kg IV with a firm ceiling of 4mg per dose, repeatable once; at 82kg the weight-based arithmetic runs past that ceiling, so the cap, not the multiplication, is what defines an adequate first dose for her — 4mg, not the 8mg the raw calculation suggests. She is still seizing on arrival, now roughly twenty-eight minutes total, well past the point most guidelines define benzodiazepine-refractory status epilepticus as having begun.
Time itself is not a passive backdrop here; it is doing real pharmacologic work against her. Benzodiazepines act by potentiating GABA-A receptor activity, but prolonged seizure activity drives a progressive internalization of synaptic GABA-A receptors away from the cell surface — the same drug class becomes measurably less effective the longer a seizure runs, independent of dose, which is part of why status epilepticus guidelines treat elapsed time itself as a variable that changes the calculus, not just a clock counting down to a second-line decision.
The guideline dosing itself isn't in question — everyone in the room agrees 2mg was too low. What's actually being debated is what to do about it now: whether to treat this as benzodiazepine-refractory and move straight to a second-line agent, or to correct the underdosing first with an adequate benzodiazepine dose before concluding benzodiazepines have failed her, given she was never actually given a real trial of them at the dose the evidence is based on — and given the receptor-internalization curve means every additional minute spent deciding is itself working against whichever drug is chosen next.
In the resuscitation bay, minute twenty-eight
She's benzodiazepine-refractory by the clock — past twenty minutes of ongoing seizure despite a benzodiazepine dose already given. I want to move to a second-line agent now rather than lose more time correcting a dose that's already been tried once.
You're right about the clock, and I'm not arguing to wait indefinitely. But 'a benzodiazepine dose already given' is doing a lot of work in that sentence — 2mg is half of the 4mg the guideline actually calls for. The 0.1mg/kg figure is capped at 4mg per dose — her weight doesn't buy her a larger single dose, it just means she was always going to sit at the ceiling. Calling this benzodiazepine-refractory treats an inadequate trial as if it were an adequate one that failed, and those aren't the same finding.
The real evidence behind benzodiazepine-refractory status is built on an adequate first dose actually being given — RAMPART (Silbergleit et al., 2012) didn't dose by weight at all, it gave every patient over 40kg a flat 4mg of IV lorazepam, which is precisely the dose she didn't get. Extending the refractory definition to cover half of that isn't applying the evidence, it's stretching past what it actually measured.
There's a way to do both without losing real time. Give a full, weight-based lorazepam dose now — not instead of preparing a second-line agent, but simultaneously, drawn up and ready to push the moment it's confirmed the adequate benzodiazepine dose genuinely hasn't worked.
That gives her the real, evidence-based benzodiazepine trial she never actually got, without adding meaningful delay to second-line therapy if it turns out she needs it — the two aren't actually in competition once the second-line drug is already at the bedside.
Agreed: full weight-based lorazepam given immediately, with a second-line agent drawn up and at the bedside in parallel rather than sequentially delayed. Seizure activity stopped within four minutes of the corrected dose.
Documented explicitly for the receiving team and for the case record: her initial dose was subtherapeutic, and this should not be read forward as “benzodiazepine-refractory status epilepticus” in her chart without that context — a distinction the team agreed mattered for how any future episode gets approached.